Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY Therapeutic Advances in Drug Safety Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI:10.1177/20420986241279128
Hongling Ma, Zhaotang Gong, Rihan Wu, GuLeng SiRi
{"title":"Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study.","authors":"Hongling Ma, Zhaotang Gong, Rihan Wu, GuLeng SiRi","doi":"10.1177/20420986241279128","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Linezolid-induced anemia (LI-AN) is a severe adverse reaction, but risk factors of the LI-AN for elderly patients have not been established.</p><p><strong>Objectives: </strong>The objective of this study was to develop a nomogram capable of predicting LI-AN in elderly patients.</p><p><strong>Design: </strong>This is a retrospective study to develop and validate a nomogram for anemia prediction in elderly patients treated with linezolid.</p><p><strong>Methods: </strong>We retrospectively screened elderly patients treated with linezolid at Inner Mongolia People's Hospital from January 2020 to December 2023 and validated our findings using the MIMIC-IV 2.2 database. Anemia was defined as hemoglobin reduction to 75% of baseline value. Univariate and multivariable logistic regression models were used to identify predictors and construct the nomogram, which was evaluated using receiver operating characteristic (ROC) curve analysis, calibration plot, and decision curve analysis.</p><p><strong>Results: </strong>A total of 231 patients were enrolled in this study. The training set comprised 151 individuals, and anemia occurred in 28 cases (18.54%). In the external validation set of 80 individuals, 26 (32.5%) were diagnosed with anemia. The predictors included duration of linezolid therapy, patient estimated glomerular filtration rate value, and sequential organ failure assessment score ⩾2. The ROC curve for the training set was 0.830 (95% CI: 0.750-0.910), while a similar ROC curve of 0.743 (95% CI: 0.621-0.865) was obtained for the validation set. The calibration curve demonstrated good correlation between predicted and observed results, indicating that this study effectively predicts risk factors associated with LI-AN in elderly patients.</p><p><strong>Conclusion: </strong>The developed prediction model can provide valuable guidance for clinicians to prevent anemia and facilitate rational linezolid use in elderly patients.</p>","PeriodicalId":23012,"journal":{"name":"Therapeutic Advances in Drug Safety","volume":"15 ","pages":"20420986241279128"},"PeriodicalIF":3.4000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425751/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420986241279128","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Linezolid-induced anemia (LI-AN) is a severe adverse reaction, but risk factors of the LI-AN for elderly patients have not been established.

Objectives: The objective of this study was to develop a nomogram capable of predicting LI-AN in elderly patients.

Design: This is a retrospective study to develop and validate a nomogram for anemia prediction in elderly patients treated with linezolid.

Methods: We retrospectively screened elderly patients treated with linezolid at Inner Mongolia People's Hospital from January 2020 to December 2023 and validated our findings using the MIMIC-IV 2.2 database. Anemia was defined as hemoglobin reduction to 75% of baseline value. Univariate and multivariable logistic regression models were used to identify predictors and construct the nomogram, which was evaluated using receiver operating characteristic (ROC) curve analysis, calibration plot, and decision curve analysis.

Results: A total of 231 patients were enrolled in this study. The training set comprised 151 individuals, and anemia occurred in 28 cases (18.54%). In the external validation set of 80 individuals, 26 (32.5%) were diagnosed with anemia. The predictors included duration of linezolid therapy, patient estimated glomerular filtration rate value, and sequential organ failure assessment score ⩾2. The ROC curve for the training set was 0.830 (95% CI: 0.750-0.910), while a similar ROC curve of 0.743 (95% CI: 0.621-0.865) was obtained for the validation set. The calibration curve demonstrated good correlation between predicted and observed results, indicating that this study effectively predicts risk factors associated with LI-AN in elderly patients.

Conclusion: The developed prediction model can provide valuable guidance for clinicians to prevent anemia and facilitate rational linezolid use in elderly patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
开发和验证利奈唑胺诱发老年患者贫血的风险预测模型:一项回顾性队列研究。
背景:利奈唑烷诱发贫血(LI-AN)是一种严重的不良反应,但老年患者发生LI-AN的风险因素尚未确定:利奈唑胺诱发贫血(LI-AN)是一种严重的不良反应,但老年患者发生LI-AN的风险因素尚未确定:本研究旨在开发一种能够预测老年患者 LI-AN 的提名图:本研究是一项回顾性研究,旨在开发和验证用于预测利奈唑胺治疗的老年患者贫血的提名图:我们回顾性筛选了2020年1月至2023年12月在内蒙古人民医院接受利奈唑胺治疗的老年患者,并使用MIMIC-IV 2.2数据库验证了我们的研究结果。贫血定义为血红蛋白降至基线值的 75%。使用单变量和多变量逻辑回归模型确定预测因素并构建提名图,使用接收者操作特征(ROC)曲线分析、校准图和决策曲线分析对提名图进行评估:本研究共纳入 231 名患者。训练集由 151 人组成,其中 28 例(18.54%)出现贫血。外部验证集有 80 人,其中 26 人(32.5%)被诊断为贫血。预测因素包括利奈唑胺治疗持续时间、患者估计肾小球滤过率值和序贯器官衰竭评估评分⩾2。训练集的 ROC 曲线为 0.830(95% CI:0.750-0.910),验证集的类似 ROC 曲线为 0.743(95% CI:0.621-0.865)。校准曲线显示预测结果与观察结果之间具有良好的相关性,表明该研究能有效预测老年患者中与 LI-AN 相关的风险因素:结论:所开发的预测模型可为临床医生预防老年患者贫血和合理使用利奈唑胺提供有价值的指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety Medicine-Pharmacology (medical)
CiteScore
6.70
自引率
4.50%
发文量
31
审稿时长
9 weeks
期刊介绍: Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.
期刊最新文献
Investigating the impact of a pharmacist intervention on inappropriate prescribing practices at hospital admission and discharge in older patients: a secondary outcome analysis from a randomized controlled trial. Determining the optimum dose of remifentanil in combination with propofol for total intravenous anaesthesia in hysteroscopy under Narcotrend and SPI monitoring. The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey. Comparison of a single intravenous infusion of alfentanil or sufentanil combined with target-controlled infusion of propofol for daytime hysteroscopy: a randomized clinical trial. Governance of artificial intelligence and machine learning in pharmacovigilance: what works today and what more is needed?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1